Invasive meningococcal disease is a worldwide problem with serious repercussions for those affected. Vaccination is recognized as the best way to combat it. The cost of vaccination is prohibitive in many low-resource settings at home and abroad. By harnessing the special immunologic properties of the skin, a dose reduction may be achieved by intradermal administration of the vaccine. The cost savings associated with dose reduction will increase availability of the vaccine.

Inclusion Criteria:

Meningococcal C naive subjects are required to fulfill all of the following criteria:

• Age ≥ 30 years
• Good health according to the investigator
• Willingness and ability to adhere to the study regimen
• Able to give informed consent

Meningococcal C experienced subjects are required to fulfill all of the following criteria:

• Age ≥ 18 years
• Good health according to the investigator
• Willingness and ability to adhere to the study regimen
• Able to give informed consent

Exclusion Criteria:

Meningococcal C naïve subjects should not have:

• Known previous invasive meningococcal infection
• Known or suspected previous vaccination against meningococcal disease
• Known or suspected allergy against any of the vaccine components
• Close contact in the last 60 days with a person known to be Neisseria positive
• History of unusual or severe reactions to any previous vaccination
• Family history of Guillain-Barré Syndrome
• Known or suspected immune deficiency, either congenital or acquired
• Administration of plasma or blood products less than three months prior to inclusion in the study
• Pregnancy (breastfeeding is allowed)
• Fertile female not conforming to prescribed contraceptive use (await first menstruation after vaccination before getting pregnant)
• Any infectious disease
• Bleeding disorders or use of anticoagulants
• Participation as a subject in another trial in the last 3 months

Meningococcal C experienced subjects should not have:

• Known or suspected allergy against any of the vaccine components
• Known previous vaccination with a quadrivalent meningococcal vaccine (either conjugate or polysaccharide)
• Close contact in the last 60 days with a person known to be Neisseria positive
• History of unusual or severe reactions to any previous vaccination
• Family history of Guillain-Barré Syndrome
• Known or suspected immune deficiency, either congenital or acquired
• Administration of plasma or blood products less than three months prior to inclusion in the study
• Pregnancy (breastfeeding is allowed)
• Fertile female not conforming to prescribed contraceptive use (await first menstruation after vaccination before getting pregnant)
• Any infectious disease
• Bleeding disorders or use of anticoagulants
• Participation as a subject in another trial in the last 3 months